Veracyte, Inc.
VCYTHealthcareNASDAQDiagnostics & Research · Last scanned Sep 8, 2026
Scan Results
Daily timeframePart of the healthcare sector, Veracyte, Inc. (VCYT) is listed under Diagnostics & Research. The $3.42B market capitalization puts VCYT squarely in mid-cap range for its industry. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.
Market Cap
$3.42B
Beta
1.93
P/E (TTM)
30.38
P/E (Fwd)
21.83
EPS (TTM)
$1.40
EPS (Fwd)
$1.95
ROE
8.8%
ROA
4.1%
Cash
$485.2M
Total Debt
$40.1M
Free CF
$106.2M
52W Change
33.0%
Annual Financials
Cash vs Debt
Where VCYT stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, VCYT finished 6.90% above its 150-day moving average ($42.33) and 6.30% above its 200-day moving average ($42.57). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VCYT overbought or oversold?
At the August 28, 2026 close, VCYT's RSI(14) was 43.7, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $485.2M in cash comfortably exceeding the $40.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $106.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 8.8%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.1% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $296.5M (2022) to $517.1M (2025), reflecting a 74% increase over the period.
Veracyte, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Veracyte, Inc. and its sector.